Intl Society for Biological Therapy of Cancer

Today marks a major advance in the fight against skin cancer, as the U.S. Food and Drug Administration (FDA) approved a new immune-based therapy for the treatment of melanoma, the leading cause of death from skin cancer.

Immunotherapy made a giant leap forward with the release of clinical trial results of BMS's ipilimumab. Results indicate that ipilimumab significantly improved the survival of patients with late stage melanoma.

The U.S. Food and Drug Administration approval of Dendreon's Provenge® (sipuleucel-T) to treat certain men with advanced prostate cancer marks a significant advance in the development of biological therapy for prostate and other forms of cancer.

A report on the recent global regulatory summit hosted by iSBTc organized by Raj K. Puri, MD, PhD of the U.S. Food and Drug Administration and Ulrich Kalinke, PhD of the Paul-Ehrlich-Institut in Germany.

A report on the recent iSBTc symposium “Anti-CTLA-4: Issues in Development and Regulatory Approval"